• Science & evidence
• Wellness
• FDA

Novo's real-world Wegovy data in MASH: what PLATINUM-Truveta and RHODIUM-2 found, and what they can't settle

By Peptide Policy Watch staff · Published November 7, 2026 · 6 min read · 6 sources, 6 checked at the source

The liver numbers from Denver are out. On Friday afternoon, November 6, Novo Nordisk released results from two real-world studies of Wegovy (semaglutide) in adults with MASH, the inflammatory, scarring form of fatty liver disease. One of them lines semaglutide up against resmetirom, the other approved MASH drug, which is a comparison patients and doctors have wanted for a while. The results lean toward semaglutide on several measures and toward resmetirom on one. The bigger story is the study design, and the release is upfront about it.

Facts are as of November 7, 2026. Sources, with retrieval dates, are at the bottom.

• 5,158adults in PLATINUM-Truveta (2,873 semaglutide, 2,285 resmetirom) [V]
• 30U.S. health systems behind the Truveta medical-record data [V]
• 6 monthslongest follow-up in the head-to-head comparison [V]

The headline numbers, in order

Novo's release, dated November 6, 2026 at 15:07 Eastern, reports both studies as presentations at AASLD's The Liver Meeting 2026 in Denver (abstracts 2461 and 2473). [V] Both used de-identified electronic medical records from the Truveta database, covering June 2021 through March 2026. [V]

PLATINUM-Truveta compared adults with MASH who started semaglutide with adults who started resmetirom. [V] At six months, the release reports these adjusted average changes from baseline: [V]

Read across the rows and the picture is mixed in a useful way. Weight, AST and blood sugar moved more in the semaglutide group. [V] ALT fell in both groups, and the difference between them wasn't statistically significant. [V] LDL cholesterol dropped more in the resmetirom group, at three months and again at six. [V] Triglycerides and HDL didn't differ significantly between groups at either time point. [V]

RHODIUM-2 asked a different question: how did people who started semaglutide compare with people with MASH who didn't? [V] It included 2,479 starters and 70,702 non-starters. [V] At 12 months, the release reports: [V]

• −14.0 vs −3.8ALT change (U/L), starters vs non-starters [V]
• −9.1 vs −1.8AST change (U/L) [V]
• −30.7 vs −2.4weight change (lb) [V]

In a subgroup whose ALT was elevated at the start, the gap was wider: ALT fell 24.3 versus 10.7. [V] Novo labels that subgroup analysis exploratory. [V] The authors' own reference list calls RHODIUM-2 a descriptive real-world data study. [V]

What these two studies are, and aren't

Both were retrospective and observational. [V] Nobody was randomly assigned to a drug. Doctors and patients chose treatments in ordinary care, and researchers looked back at the records. Novo's release says it plainly: treatment wasn't randomized, the groups differed at baseline, and associations can be shown while cause and effect can't be definitively established. [V]

The release lists more limits, and each one matters for reading the table above: [V]

• Who got counted. Results came from patients with follow-up measurements who stayed on treatment long enough to meet persistence criteria. People who stopped early drop out of the picture.
• Unmeasured confounding. Statistical weighting (inverse probability of treatment weighting) tries to balance the groups, but it can only balance what's in the records.
• Short follow-up. Both drugs are recent MASH approvals, so the data window is limited.
• Record quality. Medical-record codes can be wrong. In PLATINUM-Truveta, MASH was identified by a diagnosis code (ICD-10 K75.81) in the prior year, not by a liver biopsy.

That last point connects to the bigger evidence picture. The numbers here are blood markers (ALT, AST) plus weight and HbA1c. [V] The approval evidence for both MASH drugs came from randomized trials that read liver biopsies. [V] Our semaglutide and the liver explainer covers the ESSENCE biopsy results and why the approval is "accelerated."

Why a real-world comparison still has value

When we searched ClinicalTrials.gov for resmetirom studies on November 7, none of the 25 registered entries was a randomized head-to-head comparison with semaglutide. [V] Until one does, studies like PLATINUM-Truveta are one of the few ways to see the two drugs side by side in thousands of ordinary patients, outside a trial's tight entry rules. [V] FDA itself describes real-world evidence as having a long track record in safety monitoring and a more limited, growing role in effectiveness questions. [V] The quality of the design is what decides how much weight a result like this can carry. Our real-world evidence explainer walks through what randomization adds and how to size up a records-based headline.

The size of the semaglutide weight gap also isn't a surprise on mechanism. Semaglutide is a GLP-1 peptide that's also approved for weight management, while resmetirom is a pill that partially activates a thyroid hormone receptor in the liver and isn't approved as a weight-loss medicine. [V] That doesn't make one "better" for the liver. The trials that would answer that haven't been run.

Where it stands with FDA

Wegovy received accelerated approval for adults whose MASH has reached moderate or advanced scarring, short of cirrhosis, on August 15, 2025, with continued approval tied to confirmatory benefit from the ongoing ESSENCE trial. [V] Resmetirom (Rezdiffra) got the first MASH approval, also accelerated, on March 14, 2024. [V] The release repeats Wegovy's boxed warning about a possible risk of thyroid tumors, cancer among them, and lists gastrointestinal effects such as nausea, diarrhea, vomiting and constipation among the most common side effects. [V] Nothing in these two posters changes either drug's label. [V] Compounded semaglutide was never part of these studies or the approval. Our GLP-1 approved vs compounded explainer covers that line.

What to watch next

Novo's preview of its Denver program also lists an ESSENCE analysis in people with a BMI under 27, scheduled as an oral presentation on Sunday, November 8. [V] That one comes from the randomized trial, so it carries different weight from these two real-world studies. The 240-week ESSENCE outcomes, covering liver events, transplants and deaths, are the readout that decides whether the accelerated approval becomes a full one. [V] If you want to check registry entries for MASH trials yourself, our clinical trial listing guide walks through the fields, and the evidence ladder shows where observational data sits among study types.

Sources (retrieved November 7, 2026)

1. Novo Nordisk, "Novo real-world studies link Wegovy 2.4 mg to reductions in liver enzymes, weight and blood sugar in adults with MASH at The Liver Meeting (AASLD) 2026," PR Newswire, November 6, 2026, 15:07 ET (references cite abstracts 2461 and 2473) [V] — https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html
2. Novo Nordisk US, preview release on semaglutide MASH and liver data at AASLD The Liver Meeting 2026, October 28, 2026 [V] — https://www.novonordisk-us.com/media/press-releases/novo-nordisk-mash-liver-data-aasld-2026.html
3. FDA, "FDA Approves Treatment for Serious Liver Disease Known as 'MASH'," August 15, 2025 [V] — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
4. FDA, "FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease," March 14, 2024 [V] — https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
5. FDA, "Real-World Evidence" program page [V] — https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
6. ClinicalTrials.gov API v2, studies with intervention "resmetirom" (25 records), searched November 7, 2026 [V] — https://clinicaltrials.gov/api/v2/studies?query.intr=resmetirom

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits